New Risk • 11h
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 73% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr78m free cash flow). Share price has been highly volatile over the past 3 months (72% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€70.9m market cap, or US$81.0m). Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Jan-Eric Österlund was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Oct 31
Dicot Pharma AB, Annual General Meeting, May 06, 2026 Dicot Pharma AB, Annual General Meeting, May 06, 2026, at 17:00 W. Europe Standard Time. Location: uppsala Sweden Annuncio • Aug 12
Dicot Pharma AB to Report Q3, 2025 Results on Oct 23, 2025 Dicot Pharma AB announced that they will report Q3, 2025 results on Oct 23, 2025 Annuncio • Jun 26
Dicot Pharma AB Announces Completion of Enrolment in the Ongoing Phase 2a Study Dicot Pharma announced that the enrolment in the ongoing phase 2a study has been completed and that all participants have been dosed. Hence, the company can now conclude that the clinical study will be completed in August. The results will be reported no later than three months thereafter. Dicot Pharma's clinical phase 2a study is fully enrolled and all participants have also been dosed. The company has previously communicated that the study is expected to be completed by mid-2025. As the last participant has now been dosed, the company can conclude that the study will be completed in August 2025, when the last participant's final clinical visit takes place. Once the study is completed, the collected data will be cleaned, the database locked, and a subsequent statistical analysis carried out before results can be reported - a process expected to take two to three months. Annuncio • May 28
Dicot Pharma Announces New Findings on Mechanism of Action: "Affects the Sensures Controlling Penile Establishes Dicot Pharma announced that the latest studies on the mechanism of action of their candidate drug LIB-01 show that it affects nerves and vascular structures which interact in creating penile erection. The results can also explain LIB-01's long-lasting effect and emphasize the differentiation to current potency drugs. Dicot Pharma has previously announced that the mechanism of action of the drug candidate LIB-01 differs from currently used potency drugs and thus has the potential to change the paradigm of erectile dysfunction management. The company is characterizing the mechanism of action of LIB-01 and now new results show that LIB-01 affects underlying structures that play a central role in penile erection. A penile erection is a vascular event that occurs in response to sexual stimulation. A dramatic increase in arterial inflow to the penis is essential for an erection and it must be accompanied by a relaxation of the erectile tissue of the penis for the cavernous bodies to fill with blood. Everything is under neural command. By analyzing gene expressions in anatomical structures involved in penile erection, Dicot Pharma has found that LIB-01 affects the nervous and vascular structures that are involved in these processes. These findings differentiate LIB-01 from today's oral potency drugs, the PDE5 inhibitors, which act within the erectile tissue facilitating blood trapping within the penis and thus depend on a sufficient arterial inflow. The fact that LIB-01 affects the underlying structures that control the inflow thus supports the company's goal of also being able to treat men who are not currently helped by PDE5 inhibitors. The change in gene expression may also explain the long-lasting effect of LIB-01 on erectile function. Gene expression is a naturally occurring process whereby information from genes is transferred to the cell's structures and functions, which is crucial for various biological functions, and the effects can be long-lasting. Dicot Pharma is now continuing to characterize the mechanism of action, including studies of specific processes in the body that could cause these gene expression changes. Annuncio • Apr 30
Dicot Pharma AB to Report Q1, 2025 Results on Apr 29, 2025 Dicot Pharma AB announced that they will report Q1, 2025 results on Apr 29, 2025 Annuncio • Apr 03
Dicot Pharma AB, Annual General Meeting, May 06, 2025 Dicot Pharma AB, Annual General Meeting, May 06, 2025, at 17:00 W. Europe Standard Time. Location: advokatfirman lindahl, vaksalagatan 10, uppsala, Sweden Annuncio • Feb 05
Dicot Pharma AB Announces the Recruitment of Participants for the Company's Clinical Phase 2a Study is Advancing at a Steady Rate Dicot Pharma AB announced that the recruitment of participants for the company's clinical phase 2a study is advancing at a steady rate, and that half of the planned 140 participants have now been dosed. All participating men have erectile dysfunction and have been in a stable relationship for at least six months. To evaluate the effect of LIB-01 on erectile function, they respond to questions from the standardized questionnaire International Index of Erectile Function. In addition, participants continuously fill out a form of diary after each sexual intercourse. About the phase 2a study: The purpose of the Phase 2a study is to evaluate the efficacy of LIB-01 in men with erectile dysfunction. The study is expected to include 140 participants and is being conducted at six clinics in Sweden (Uppsala, Stockholm, Gothenburg and Linköping), Denmark (Herlev) and the Netherlands (Groningen). Each person will participate in the study for eight weeks after dosing. The trial is double blind and placebo controlled. This means that neither the clinical staff administering the study drug, nor the participants, know which research subjects are receiving LIB-01 and which are receiving placebo. The clinical part of the study is expected to last until mid-2025. This will be followed by a statistical analysis before the results can be reported. Annuncio • Dec 19
Dicot Pharma AB (publ) Announces That the United States Patent and Trademark Office Grants an Additional Patent for Its Efficacy Drug Candidate, LIB-01 Dicot Pharma announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent for its erectile dysfunction drug candidate, LIB-01. The patent is part of a patent family now gaining full approval in the US with protection until 2042. This family is paramount in the company's IP-work and significantly strengthens both product and method protection. The newly granted patents extend both product and method protections in the US until 2042. Dicot Pharma plans to file for corresponding patents in additional geographic regions worldwide. Annuncio • Nov 27
Dicot Pharma AB Receives New Patent in the USA Dicot Pharma AB announced that the US Patent and Trademark Office has granted a new patent covering important steps in the manufacturing of the potency drug candidate LIB-01. Dicot Pharma has received a new patent approved in the US that protects key steps in the manufacture of LIB-01 and is valid until 2042. Dicot Pharma has previously received a Notice of Allowance for a total of three patent applications in the US, and this is the first of these to be formally approved. Annuncio • Nov 08
Dicot Pharma Announces Initiation of Phase 2A Clinical Study After recently receiving approval from authorities, the potency drug developer Dicot Pharma's clinical phase 2a study has now started. The primary objective of the study is to evaluate the efficacy of LIB-01 in patients with erectile dysfunction. Recruitment for the phase 2a study began immediately after the authority's approval and is managed by the company's clinical partner CTC, which is conducting the study. Now the company announces that the study has formally started as the first screening visit has taken place. The primary objective of the phase 2a study is to evaluate LIB-01's efficacy in patients with erectile dysfunction. The study will enroll 140 male participants and will be conducted at six clinics across Sweden, Denmark and the Netherlands. Each patient will participate for eight weeks after initial dosing. The study is double-blind, and placebo controlled, meaning that neither the clinical staff who administer the study drug nor the participants will know which research subjects are receiving LIB-01 and which are receiving placebo. As Dicot Pharma previously announced, the clinical part of the study is expected to last until the middle of 2025. A statistical analysis will then follow before the results can be reported. New Risk • Nov 08
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 185% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (185% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€35.5m market cap, or US$38.3m). Annuncio • Sep 17
Dicot Pharma AB (publ) Provides an Operational Update Dicot Pharma AB announced that following the successful outcome of Dicot Pharma's rights issue, an operational update is being presented on September 17, 2024. The company will continue to focus on the development of its potency drug candidate, with a phase 2a study set to commence soon. Additionally, the operational plan includes advancing R&D activities, a listing on Nasdaq First North, and initiating preclinical studies for new indications within metabolic diseases. Dicot Pharma's rights issues in August was oversubscribed, and an over-allotment option was exercised, resulting in a total of approximately SEK 135 million before costs to the business. This gives the pharmaceutical company a strong financial position. As the company announced in June, results from animal studies within the framework of LIB-01's research program show that the substance unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes, and high blood pressure. Based on these promising results and the successful outcome of the rights issue, Dicot Pharma's board and management have conducted a strategic review, which now forms the foundation of the operational plan, where the primary focus will continue to be on the clinical development of the potency drug candidate LIB-01. A phase 2a trial is set to begin in the fourth quarter. The company remains on track with its previously communicated timeline regarding all preparations, and the clinical trial application was submitted in July 2024. The placebo-controlled trial, involving approximately 140 patients, aims to demonstrate a statistically significant effect of LIB-01 in improving erectile function in patients with erectile function. The company advances certain R&D activities related to upcoming development phases, including tablet development, scaling up the manufacturing process, and preparations to open an Investigational New Drug Application (IND) in the USA, which is required for conducting clinical trials there. The company will also make other important preparations required for clinical phase 2b. In addition to the development of the potency drug candidateLIB-01, the company's strong financial position allows for the initiation of a preclinical development program in metabolic diseases. A comprehensive market analysis conducted by an external party on behalf of Dicot Pharma has been matched against the company's own available results in metabolic diseases, which in total strongly justifies further research into a number of prioritized indications. In the fourth quarter, the company intends to apply for listing on the Nasdaq First North Growth Market, as it is assessed to support Dicot Pharma's continued development, internationalization, and competitiveness. The listing will enable a broader and more international shareholder base and is anticipated to generate increased interest in the share from stakeholders and analysts. In line with the business strategy for LIB-01, i.e., entering partnerships with larger pharmaceutical companies to finance and further develop the drug for the world market, the strong outcome of the rights issue puts Dicot Pharma in a favorable position. Efforts to engage with potential partners will now be established alongside the phase 2a study and will be carefully managed by the board and management to maximize shareholder value. Annuncio • Jul 25
Dicot Pharma AB to Report Q2, 2024 Results on Aug 23, 2024 Dicot Pharma AB announced that they will report Q2, 2024 results on Aug 23, 2024 Annuncio • Jul 08
Dicot Pharma Announces Clinical Trial Application for Phase 2A Trial Dicot Pharma announced that a clinical trial application for a phase 2a trial with the drug candidate LIB-01, has been submitted. The trial is planned to start in the fourth quarter of 2024 as previously communicated. The trial is fully funded with the amount secured in advance in the announced rights issue that the company intends to carry out in August. Dicot is developing a new potency drug with the aim to treat erectile dysfunction better than existing drugs on the market. With good results from the company's recently completed phase 1 trial, a clinical trial application for a phase 2a trial has now been submitted. It is a so-called "proof of concept", with the main objective of demonstrating that LIB-01 can improve erectile function in patients with erectile dysfunction. The trial, which is placebo-controlled and double-blind, will include approximately 140 participants and will be conducted at clinics in Sweden, Denmark and the Netherlands. The start of the trial is planned for the fourth quarter of 2024, when the first patient is expected to start treatment with LIB-01. Through the commitments obtained in advance in the rights issue that the company intends to carry out in August, the trial is fully financed. Annuncio • Jul 04
Dicot Pharma AB to Report Q3, 2024 Results on Aug 01, 2024 Dicot Pharma AB announced that they will report Q3, 2024 results on Aug 01, 2024 Annuncio • Jul 02
Dicot Pharma AB Completes a Pre-IND Meeting with FDA Dicot Pharma AB announced that the company has held a pre-IND meeting with the US Food and Drug Administration (FDA) and received positive feedback on the development program for the drug candidate LIB-01. This is considered a validation of the quality of the program and is an important step towards an application to include US study centers in future clinical studies and to ensure that the current development plan meets the regulatory requirements for future market approval in the US. Dicot Pharma has recently had its first formal interaction with the US Food and Drug Administration (FDA) via a pre-IND meeting where the agency gave its feedback in writing. An early interaction with FDA is considered valuable to reach a consensus on the structure and objectives of a development program and ultimately secure market approval in the United States. A pre-IND meeting precedes the opening of an Investigational New Drug (IND) application in the United States, which is required to be able to include US study centers in future clinical studies. The main purpose of the meeting was to obtain the Agency's views on the overall development program for LIB-01 in general and the upcoming Phase 2a study in particular. Based on the submitted background material, the FDA provided its views on study design, preclinical development, chemistry, manufacturing, and quality controls. In essence, the company considers that the agency's feedback was positive and helps to ensure that the development program meets the regulatory requirements for the US market. Annuncio • Jun 08
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs Dicot Pharma AB is developing LIB-01 into a new potency drug with improved properties compared to currently available drugs. New research results on LIB-01 show that the substance appears to influence factors linked to certain metabolic diseases. Based on these research results, the company has submitted a patent application for the treatment of several new indications. Dicot Pharma is developing the potency drug candidate LIB-01 with the aim of offering a treatment that surpasses current drugs, including a long-term effect on erectile function. Within the framework of research on LIB-01, the company has received new results from animal studies showing that the substance unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes and high blood pressure. The company has filed a new patent application to seek protection for the treatment of these indications. Based on these promising results and the currently filed patent application, Dicot's Board of Directors and management will conduct a strategic review during the third quarter of 2024 to determine how these new research results should be taken forward by the company and complement the existing product portfolio in sexual dysfunctions. Annuncio • Apr 24
Dicot AB (publ) Announces Positive Safety and Improved Efficacy Results from Phase 1 Study Dicot AB (publ) completed phase 1 clinical study demonstrates that the company's drug candidate LIB-01 has a very good safety profile, which was the primary objective of the study. In addition to this, the company can deduce an efficacy signal from the study where participants reported an improved erectile function, in some cases beyond 28 days post first dose. The primary objective of Dicot's phase 1 study has been to investigate the safety profile in humans for LIB-01, the company's drug candidate for treatment of erectile dysfunction. In January, Dicot reported good results from the first part where participants received single dosing (a so-called SAD study). Dicot has now locked the database for the final part of the study where the participants were given repeated dosing. Based on today's readout of data, the company can now announce that LIB-01 demonstrated a very good safety profile. No serious adverse effects occurred and there were no dropouts due to adverse events. Only occasional and mild adverse effects were reported in participants receiving LIB-01. Dicot can also see an efficacy signal from the MAD part, in which 24 otherwise healthy men with erectile dysfunction participated and were dosed for three days. An improvement in erectile function has been reported, which was captured by subjective self-report questionnaires and supported by objective measurements using a Viagra®? device. Participants also reported that the improved erectile function lasted for a long time, in some cases the effect remained at the end of the study, i.e., 28 days post first dose. Later in the second quarter, Dicot will be able to provide an in-depth summary of results where the above results will be presented in more detail. The exploratory efficacy measurements will provide important data for the design of the company's planned phase 2a study. The efficacy signal that Dicot has noted must be confirmed in a clinical phase 2a study to provide a definitive "proof-of-concept", i.e. a statistically significant result from a larger group of participants. The study is planned to start in the second half of 2024. Annuncio • Apr 08
Dicot AB (publ) to Report Q1, 2024 Results on May 06, 2024 Dicot AB (publ) announced that they will report Q1, 2024 results on May 06, 2024 Annuncio • Mar 12
Dicot AB (publ) Announces Recruitment Completed in Dicot's Phase 1 Trial Dicot AB (publ) announced that the recruitment to the final part of its phase 1 study is completed. The study is thus proceeding according to the previously communicated timeline and the results are expected to be announced during the second quarter. Dicot's phase 1 study, aiming at investigating the safety profile in humans, started in August 2023 and consists of two parts: SAD (single dose) and MAD (multiple doses). The study is placebo-controlled and double-blind, meaning that some participants receive LIB-01 and some receive placebo, and neither the participant nor the physician knows which of the two was dosed. In January 2024, Dicot announced the first results from the SAD, which showed that the drug candidate LIB-01 has a very good safety profile. There were no serious side effects, nor were dose increases limited by any side effects. The MAD includes some 25 participants divided into different dose groups where the dosage is increased between the different groups. Dicot has now recruited the last participant, which means that the study is progressing according to plan. Overall results are expected to be announced in the second quarter of 2024, as previously communicated by the company. Annuncio • Jan 29
Dicot AB (publ) to Report Fiscal Year 2023 Results on Feb 26, 2024 Dicot AB (publ) announced that they will report fiscal year 2023 results on Feb 26, 2024 Annuncio • Jan 23
Dicot AB (publ) Presents Positive Results from the First Part of its Phase 1 Clinical Study Dicot presents positive results from the first part of its phase 1 clinical study showing that LIB-01 has a very good safety profile. There were no serious adverse effects. The results also show that the drug is well absorbed in the body, which puts the company in a strong position for clinical phase 2. The primary objective of Dicot's phase 1 study is to investigate the safety of the potency drug candidate LIB-01 in humans. The study is double-blind and placebo-controlled and consists of two parts: SAD and MAD. The SAD part studies increasing single doses of LIB-01 regarding safety parameters such as adverse effects as well as how well the drug is absorbed in the body. In the MAD part, the same assessments are done, but with repeated dosing. The company announces the first overall results from the SAD part, showing a very good safety profile. The company announced the first overall results from the MAD, the second and final part of the phase 1 study, will be published in the second quarter of 2024. Annuncio • Jan 11
Dicot Applies for Patent Covering New Manufacturing Technology Dicot has applied for a patent covering a novel technology to manufacture the starting material for its potency drug candidate. It concerns a custom-designed approach in cell cultivation developed in partnership with Uppsala University. In 2022, Dicot started a research project with Uppsala University and W. Szafer Institute of Botany to investigate whether the starting material for the drug candidate LIB-01 could be produced by using plant cells grown in cultures; an established technology for large-scale commercial production of many medicinal substances originally derived from nature. According to the company, the project - in which a custom-designed method is used to produce cells and grow them - has been successful in demonstrating at a laboratory scale that the technology works. Therefore, the project will now progress to larger-scale testing. At the same time, a patent application is submitted to the Swedish Patent and Registration Office to protect this way of producing the starting material. The action will be followed by further patent applications on several other relevant markets. Annuncio • Dec 15
Dicot AB (publ) Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year Dicot AB (publ) concluded the clinical part of the SAD, earlier than initially planned. Consequently, the company will be able to report these results already in the January-to-February transition. Results from the second and final part of the phase 1 trial are expected to be communicated in the second quarter of next year, as previously announced. Dicot's phase 1 trial of the potency drug candidate LIB-01 is placebo-controlled and double-blinded, with the primary objective of investigating the safety profile in humans. The trial started in August of this year and consists of two parts: SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose). On December 14, 2023, the last participant in the SAD completed his final clinic visit, signifying that all participants have been dosed and undergone subsequent safety follow-up. Now, a period of data cleaning and analysis remains. Dicot previously communicated that the trial results were expected to be presented during spring 2024. However, as the company now has successfully gathered all necessary data in the SAD earlier than originally planned, these results can be communicated already in the January-February month transition. Simultaneously, the MAD is progressing as scheduled, with the first group of participants having received doses. Results from the MAD are expected to be communicated in the second quarter of 2024, as previously communicated. Annuncio • Oct 29
Dicot AB, Annual General Meeting, May 06, 2024 Dicot AB, Annual General Meeting, May 06, 2024. Agenda: To consider determination of fees and other compensation for the board and its committees, divided between the chairman and other board members; to consider determination of fees for auditors; to consider election of board members and chairman of the board; to consider election of auditors; and to consider Principles for the Nomination committee's composition and work ahead of the 2025 AGM. Annuncio • Oct 25
Dicot AB Initiates Repeated Dosing in Phase I Study Dicot AB recently entered phase I with its drug candidate LIB-01, where the first step is to test single dosing on healthy volunteers. In parallel, the company is now starting the second part of the study, testing repeated dosing of the candidate. The first results from the study are expected in the spring. Annuncio • Oct 20
The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023 In August, Dicot's phase 1 study was initiated, with single dosing of the participants. Concurrently, the second part of the study starts October 20, 2023 where safety of LIB-01 is now being studied with repeated dosing. Dicot's first clinical study in humans with the potency drug candidate LIB-01 started in August and is in full swing. Initially, participants were administered a single dose, called Single Ascending Dose (SAD). Now, in parallel, the study is moving into next part where new participants receive repeated dosing, also called Multiple Ascending Dose (MAD). Today, the first screening visit takes place to identify participants for the MAD part's first dose group. The screening means that applicants are examined based on a variety of selection criteria for participation in the study. As the company previously announced, this is a placebo-controlled phase 1 clinical trial with the primary objective to evaluate the safety profile of LIB-01 in humans. The entire study is double-blinded, which means that some participants receive LIB-01 and some receive a placebo, and that neither the participant nor the physician knows which of the two was dosed. Annuncio • Oct 02
Dicot AB to Report Q3, 2023 Results on Oct 31, 2023 Dicot AB announced that they will report Q3, 2023 results on Oct 31, 2023 Annuncio • Sep 27
Dicot AB Applies for International Patent Protection Dicot has submitted an international patent application through the Patent Cooperation Treaty, enabling for protection in 157 countries. The patent application covers drug substances in development and their manufacturing methods. Dicot has filed a patent application through the Patent Cooperation Treaty (PCT) covering 157 countries, encompassing all key markets. The application includes relevant drug substances currently in development, their composition, and their manufacturing methods. Granted patents will provide comprehensive protection for Dicot's drug candidate, LIB-01. But the application itself already offers indirect protection in all these markets throughout the process. A PCT application is initially reviewed by a patent authority selected by the company. The authority's opinion then forms the basis for further handling by the respective authorities responsible for the various markets the company decides to pursue. The PCT process significantly streamlines the procedure and makes it more cost-effective, and it is used by most leading pharmaceutical companies. Dicot has chosen the European Patent Office as the first reviewing authority, which also allows for a shorter lead time regarding granted patents in Europe. Although the USA is included in the PCT application, Dicot has also submitted the same patent application directly to the United States Patent and Trademark Office through a fast-track program called the Patent Prosecution Highway (PPH). This is done with the aim of expediting the grant of a patent in what the company considers a key market. The same patent application was previously submitted to the Swedish Patent and Registration Office, enabling the PPH application strategy. Annuncio • Sep 05
Dicot AB Announces First Participants Dosed in Phase 1 Trial Dicot announced that the first study participants have been dosed in the company's clinical phase 1 trial. Dicot has recently started the first clinical trial with its potency drug candidate LIB-01. The primary objective of the study is to evaluate the safety of LIB-01 and consists of two parts: single dosing and repeated dosing. The recruitment of healthy participants for the first part of the study, the single dosing, started immediately after approval from the authorities and the first participants have been dosed. The trial is performed at the University Hospital in Uppsala, where the company's partner CTC has its clinic. The single-dose part of the study involves around 50 participants, divided into different dose groups and where the doses are gradually increased in subsequent groups. After dosing, participants are admitted for a period of three days during which frequent safety assessments are conducted, including blood sample collection, blood pressure monitoring, and ECG, all of which are standard procedures in this type of first-in-human study. The single dosing will be followed by the second part of the study where repeated doses are given to each of the participants. The entire phase 1 trial is double blinded and placebo-controlled, which means that some participants receive LIB-01 and some receive placebo and that neither the participant nor the investigator know who receives LIB-01 and who receives placebo. Annuncio • Aug 30
Dicot AB Applies for US Patent Dicot announced that a patent application has been submitted to the US Patent Office. The application covers the new oral drug formulation of the candidate LIB-01 which is now used in the ongoing phase 1 clinical study. Dicot submitted a patent application to the United States Patent and Trademark Office. It concerns patententing a method of formulating LIB-01 that enables an oral intake of the active substance. The new oral formulation was developed in 2022 and is now being used in the company's clinical phase 1 study. Dicot announced last year that the company had submitted a new patent application covering new production methods and chemical compounds. Now Dicot is converting yet another of the company's trade secrets into a patent. The application is a so-called provisional patent application that aims to get an approved patent in the United States. Shortly, this will be followed by an application to the Swedish Patent and Registration Office where the application can later be expanded to other markets. Board Change • Aug 29
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Chairman of the Board Eva Saers is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.